Advertising

Pfizer Inc

PFE-N

NYSE:PFE

43.06
1.34 (3.21%)
Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. Pfizer is considered one of the world's largest pharmaceutical companies.
More at Wikipedia

Analysis and Opinions about PFE-N

Signal
Opinion
Expert
Chart
BUY
BUY
May 14, 2021

Opportunity for Pfizer and J&J are solid. You give up some appreciation when you select a stock with higher yield. However, total return is the most important. There is more diversification with JNJ with medical supplies. Pfizer's partnership with BioNtech is positive. There is renewed chatter about drug price controls. Both offer good prospective.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
May 14, 2021

Opportunity for Pfizer and J&J are solid. You give up some appreciation when you select a stock with higher yield. However, total return is the most important. There is more diversification with JNJ with medical supplies. Pfizer's partnership with BioNtech is positive. There is renewed chatter about drug price controls. Both offer good prospective.

JoAnne Feeney
Price
$40.080
Owned
Unknown
WAIT
WAIT
April 30, 2021
They report Tuesday. Despite a successful Covid drug, the stock has done nothing because they have a slew of patents about to expire. That said, it's a fine stock with good managers and a safe dividend yield. You could to a lot worse. You would wait before the report.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
April 30, 2021
They report Tuesday. Despite a successful Covid drug, the stock has done nothing because they have a slew of patents about to expire. That said, it's a fine stock with good managers and a safe dividend yield. You could to a lot worse. You would wait before the report.
Jim Cramer - Mad Money
Price
$38.650
Owned
Unknown
DON'T BUY
DON'T BUY
April 22, 2021

Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
April 22, 2021

Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.

David Burrows
Price
$38.685
Owned
No
DON'T BUY
DON'T BUY
April 13, 2021
Their vaccine has been a boon to their revenues, which jumped 30% in a one year, but this is likely a round trip. Also, margins on this vaccine are fairly low. The vaccine offers some benefit to PFE, but it's limited. Look elsewhere.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
April 13, 2021
Their vaccine has been a boon to their revenues, which jumped 30% in a one year, but this is likely a round trip. Also, margins on this vaccine are fairly low. The vaccine offers some benefit to PFE, but it's limited. Look elsewhere.
Gordon Reid
Price
$37.105
Owned
Unknown
PARTIAL BUY
PARTIAL BUY
April 9, 2021
Price momentum and valuation has not lined up. It is a low volatility stock with good yield. Almost a bond replacement from the stable and reasonably priced business. Not the cheapest on EBITDA, cashflow or book value. Solid balance sheet.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
April 9, 2021
Price momentum and valuation has not lined up. It is a low volatility stock with good yield. Almost a bond replacement from the stable and reasonably priced business. Not the cheapest on EBITDA, cashflow or book value. Solid balance sheet.
Jason Mann
Price
$36.600
Owned
Yes
DON'T BUY
DON'T BUY
March 19, 2021

As a general comment, the margins on the vaccines are not great by design. Their revenues in 2021 will grow quite smartly. The company has been stuck in the mud for some time. There will be 10% revenue growth. However, he fears it will be a one off. There is not a lot of opportunity for top line growth. There has been consolidation in the space to cut costs. Biopharma space is more positive, like Abbvie.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
March 19, 2021

As a general comment, the margins on the vaccines are not great by design. Their revenues in 2021 will grow quite smartly. The company has been stuck in the mud for some time. There will be 10% revenue growth. However, he fears it will be a one off. There is not a lot of opportunity for top line growth. There has been consolidation in the space to cut costs. Biopharma space is more positive, like Abbvie.

Gordon Reid
Price
$35.530
Owned
No
BUY
BUY
March 18, 2021

PFE vs. NVAX He'd absolutely go with PFE. Investors have been chasing growthy parts of the market and ignoring the stable areas. Vaccines don't move the needle for PFE the way they do for the others. A great long-term investment if you think rates will stay lower. Mature, decent balance sheet, good valuation.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
March 18, 2021

PFE vs. NVAX He'd absolutely go with PFE. Investors have been chasing growthy parts of the market and ignoring the stable areas. Vaccines don't move the needle for PFE the way they do for the others. A great long-term investment if you think rates will stay lower. Mature, decent balance sheet, good valuation.

John Zechner
Price
$35.815
Owned
Unknown
DON'T BUY
DON'T BUY
February 19, 2021
Their vaccine will give them a boost in the near term, but it is not sustainable for their long term growth outlook. Their product pipeline is really hampering their growth outlook. Needs more visibility in their pipeline. It will continue to be depressed until there is movement here.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
February 19, 2021
Their vaccine will give them a boost in the near term, but it is not sustainable for their long term growth outlook. Their product pipeline is really hampering their growth outlook. Needs more visibility in their pipeline. It will continue to be depressed until there is movement here.
Christine Poole
Price
$34.440
Owned
Unknown
HOLD
HOLD
February 17, 2021
He is focused on US healthcare sector, though he's not looking at the vaccine angle. You'll do fine long term. Reasonably valued, development potential. There will be an overhang as some of the fast money comes out and goes to pharma companies left in the dust.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
February 17, 2021
He is focused on US healthcare sector, though he's not looking at the vaccine angle. You'll do fine long term. Reasonably valued, development potential. There will be an overhang as some of the fast money comes out and goes to pharma companies left in the dust.
James Telfser
Price
$34.880
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
February 11, 2021
(A Top Pick Jan 17/20, Down 15%) Committed to transitioning to a more pure play R&D-focused biopharmaceutical company. But it hasn't delivered. Consumer businesses are being spun out. Great vaccine business, but there's competition. OK at current valuations. Risk profile has changed. Finances will be impacted by number of vaccines actually needed.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
February 11, 2021
(A Top Pick Jan 17/20, Down 15%) Committed to transitioning to a more pure play R&D-focused biopharmaceutical company. But it hasn't delivered. Consumer businesses are being spun out. Great vaccine business, but there's competition. OK at current valuations. Risk profile has changed. Finances will be impacted by number of vaccines actually needed.
Paul MacDonald
Price
$34.450
Owned
Yes
PAST TOP PICK
PAST TOP PICK
February 8, 2021
(A Top Pick Feb 11/20, Up 1%) You are looking for their dividend but a lot of it sold off during 2020 and he eventually sold off in November on the vaccine news. He moved to another vaccine company.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
February 8, 2021
(A Top Pick Feb 11/20, Up 1%) You are looking for their dividend but a lot of it sold off during 2020 and he eventually sold off in November on the vaccine news. He moved to another vaccine company.
Jamie Murray
Price
$34.820
Owned
No
WEAK BUY
WEAK BUY
February 1, 2021

He likes it. It is a way to play the vaccines. He has had MRNA-Q in the portfolio for a while. The growth of vaccines will be with us for some time. He feels the growth is there. He prefers to play the group through an ETF like XBI-T. You are going to see more money spent in vaccinations and they will be with us for a long, long time.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
February 1, 2021

He likes it. It is a way to play the vaccines. He has had MRNA-Q in the portfolio for a while. The growth of vaccines will be with us for some time. He feels the growth is there. He prefers to play the group through an ETF like XBI-T. You are going to see more money spent in vaccinations and they will be with us for a long, long time.

John Zechner
Price
$35.890
Owned
Unknown
DON'T BUY
DON'T BUY
January 19, 2021

They're not in warp speed now, given the problems in vaccine distribution in various states. Pfizer's problem is that it isn't innovative like Eli Lilly or Bristol-Myers.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 19, 2021

They're not in warp speed now, given the problems in vaccine distribution in various states. Pfizer's problem is that it isn't innovative like Eli Lilly or Bristol-Myers.

Jim Cramer - Mad Money
Price
$36.730
Owned
Unknown
DON'T BUY
DON'T BUY
January 14, 2021

An area that's started to act better recently. Well managed. But doesn't understand what the catalysts are. Doesn't find it compelling. Consider the picks and shovels instead, like Agilent or Danaher, who benefit from growth in everyone's pipeline.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 14, 2021

An area that's started to act better recently. Well managed. But doesn't understand what the catalysts are. Doesn't find it compelling. Consider the picks and shovels instead, like Agilent or Danaher, who benefit from growth in everyone's pipeline.

David Fingold
Price
$36.920
Owned
No
DON'T BUY
DON'T BUY
January 11, 2021
It has an interesting problem. It has the solution to COVID-19 and they have orders for billions of doses but the stock has not done anything. The earnings forecast for the company are going sideways. Analysts probably think the demand for COVID vaccines will decline sharply when COVID is over and then there will be all these plants that are idle. So looking longer term, they see the earnings as flat.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 11, 2021
It has an interesting problem. It has the solution to COVID-19 and they have orders for billions of doses but the stock has not done anything. The earnings forecast for the company are going sideways. Analysts probably think the demand for COVID vaccines will decline sharply when COVID is over and then there will be all these plants that are idle. So looking longer term, they see the earnings as flat.
Ross Healy
Price
$37.645
Owned
Unknown
Showing 1 to 15 of 710 entries

Pfizer Inc(PFE-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 11

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 16

Total Signals / Votes : 28

Stockchase rating for Pfizer Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Pfizer Inc(PFE-N) Frequently Asked Questions

What is Pfizer Inc stock symbol?

Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N

Is Pfizer Inc a buy or a sell?

In the last year, 28 stock analysts published opinions about PFE-N. 11 analysts recommended to BUY the stock. 16 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Pfizer Inc.

Is Pfizer Inc a good investment or a top pick?

Pfizer Inc was recommended as a Top Pick by JoAnne Feeney on 2021-05-14. Read the latest stock experts ratings for Pfizer Inc.

Why is Pfizer Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Pfizer Inc worth watching?

28 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.

What is Pfizer Inc stock price?

On 2021-07-28, Pfizer Inc (PFE-N) stock closed at a price of $43.06.